Method for preparing 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil)

US8324412B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Detlef Grawe · Kleinromstedt, DE
• Sabine Gliesing · Jena, DE
• Hagen Gerecke · Jena, DE
• Peter Hoesel · Jena, DE
• Uwe Mueller · Jena, DE
• Thomas Michel · Leipzig, DE
• Robert Eilers · Jena, DE
• Uwe Knabe · Trockenborn, DE
• Bernd Erhart · Kahla, DE
• Michael Mosebach · Berlin, DE
• David Voigtlaender · Bad Vilbel, DE
• Ulf Tilstam · Berlin, DE
• Jürgen Jacke · Unna, DE
• Klaus Bahl · Herne, DE
• Ulf Bohlmann
• Dieter Wehmeier · Bergkamen, DE
• Michael Sander · Frechen, DE

Key dates

• Filing date: Jan 10, 2011
• Grant date: Dec 4, 2012
• Expiry date: Jan 10, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T428/2982
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).